CTI BioPharma Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has extended the…

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Powerful Moments of Peace During Protests

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam eros ante, placerat ac pulvinar at, iaculis…